GLP-1 drug demand rising, but not all packaged food companies in the crosshairs

October 08, 2024 10:09 AM AEDT | By Investing

Google News:

GLP-1 drug demand rising, but not all packaged food companies in the crosshairs

Recent News

Zuellig Pharma Launches "Obesity is a Disease" Seminar as Part of "Red...

Nova Eye Medical (ASX:EYE) Surges Ahead with Record FY25 Revenues

ASX 200 Slides as RBA Surprises Market With Rate Pause Decision

Soma Gold Expands Colombian Footprint with La Escondida Mine Acquisiti...

Investing.com -- As signs emerge that demand for GLP-1 drugs is stronger than expected, many are fearing the worst for packaged-food companies, but Bernstein believes that some companies are likely to fare better than others as patients on these weight-loss drugs shift appetite in favor of more protein-based foods.

"While we cannot categorically determine how big the compounding market is for GLP-1 drugs in the U.S. today, there are several indicators that suggest the market may be larger than we previously thought," analysts at Bernstein said in a Thursday note.

While official data from IQVIA suggests only about 1.4% of U.S. adults are currently taking branded GLP-1 drugs like Ozempic and Wegovy, there are signs that demand is stronger than expected/

Survey data indicates that as much as 12% to 13% of U.S. adults have taken or are currently taking GLP-1 drugs, analysts at Bernstein said, with approximately 8% currently using them for either diabetes or weight loss.

This discrepancy between the survey and IQVIA data point to a potentially larger market for compounded GLP-1 drugs than previously thought.

Evidence suggests that compounding pharmacies, which create custom-made medications for individual patients based on prescriptions and can produce versions of certain drugs during shortages, could be "reaching a larger number of GLP-1 patients than are captured in the official branded drug data."

While the signs of increased demand are expected to dent appetite for packaged foods, Bernstein believes that some companies such as Campbell Soup Company (NYSE:CPB) could fare better than others as GLP-1 patients are shown to have an increased appetite for protein-based foods.

Bernstein upgraded Campbell Soup Company (NYSE:CPB) from Market-Perform to Outperform, and its price target raised from $55 to $58 as evidence shows that GLP-1 users favor more protein rich foods and beverages.

Hershey Co (NYSE:HSY), however, was downgraded from Outperform to Market-Perform and its target price cut from $230 to $205 on worries volume recovery will struggle as GLP-1 demand appears to be on the up and up.

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.